Pharmaceutical Industry

Cabaletta Bio GmbH 

Basel · Since 2024

Cabaletta Bio GmbH is a clinical‑stage biotechnology company developing engineered T cell therapies for autoimmune diseases. It applies the Cabaletta Approach to B cell Ablation (CABA®) platform and is advancing rese‑cel, a fully human CD19‑CAR T candidate, in RESET™ Phase 1/2 trials to evaluate transient B‑cell depletion as a means to reset the immune system in conditions such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris.

Cancer Research and Biotechnology AG 

Baar · Since 2017

The core activity of Cancer Research and Biotechnology AG is the development of oncological drugs to combat aggressive types of cancer with high unmet medical needs. The company aims to improve the patient journey through an accelerated clinical regulatory pathway and reduce the burden of conventional treatments.

Canexis Pharma AG 

Schlattingen · Since 2020

The core activity of Canexis Pharma AG is the provision of services in the pharmaceutical industry, including the development, manufacture and quality assurance of pharmaceutical products. The company also offers services to non-pharma customers, but the main focus is on the pharmaceutical industry.

GlobeMed Pharma Group AG 

Cham · Since 1999

The core activity of Cannapharm AG is the production and distribution of cannabis extracts and other cannabis-based products for medical purposes. The company specializes in the manufacture of high-quality cannabis extracts, which are cultivated and produced in Switzerland, and offers these products to the specialist trade and pharmaceutical industry.

CAPTOR THERAPEUTICS GmbH 

Allschwil · Since 2018

The core activity of Captor Therapeutics is the development of medicines, particularly in the early stages of drug development, with a focus on reprogramming proteins to treat previously incurable diseases.

CARBOGEN AMCIS AG 

Bubendorf · Since 1982

CARBOGEN AMCIS AG is a CDMO providing development and manufacturing services for drug substance (APIs) and drug product. Services include process development, GMP and non-GMP manufacturing, sterile injectable production, cholesterol and vitamin D specialties, and support functions such as quality management, regulatory affairs and project management.

Cardio-CARE AG 

Davos Wolfgang · Since 2019

The core activity of Cardio-CARE AG is the implementation of research projects and services in the field of cardiovascular diseases and personalized medicine. This includes: planning, conducting and analyzing clinical trials on cardiovascular diseases and personalized medicine; supporting the planning, conducting and analyzing of studies on medical devices, such as telemonitoring; biostatistical and bioinformatic consulting; high-throughput genome sequence data analysis; and the application of artificial intelligence and machine learning in data analysis. The company thus offers a combination of research, services and consulting in the field of cardiovascular diseases and personalized medicine.

Catalent Pharma Solutions GmbH 

Cham · Since 2000

Catalent Pharma Solutions GmbH is a global contract development and manufacturing organization (CDMO) providing development, manufacturing and supply services to pharmaceutical, biotech and consumer health companies. Services include oral dose and softgel technologies, biologics and specialty manufacturing, clinical supply and formulation and delivery technology support.

CCBD Sàrl 

Neuchâtel · Since 2021

CCBD Sàrl is a producer of CBD products, particularly CBD-containing cannabis grown indoors using state-of-the-art technology and in compliance with good manufacturing practices (CGMP). The company's core activity encompasses the cultivation, production, and distribution of CBD products such as flowers, oils, extracts, and other CBD-containing articles.

CDC LAB SA 

Plan-Les-Ouates · Since 2021

The core activity of CDC LAB SA is the production and distribution of medical cannabis and related products, in particular dried flowers and pharmaceutical active ingredients, which are manufactured under strict quality controls and GMP guidelines. The company also provides consulting services to healthcare professionals and pharmacies regarding the use and application of medical cannabis.

CDR-Life AG 

Horgen · Since 2017

The company develops and commercializes new medicines, particularly T-cell activated cancer medicines, and provides services in the areas of research and development, clinical trials, pharmacology, toxicology and analytics.

Cedem AG 

Zurich · Since 1991

The core activity of CEDEM AG is the development, manufacture and marketing of dietary supplements, vitamins and minerals that meet traditional Swiss quality standards. The company offers a wide range of products tailored to the specific health needs of women, men and children, including products for healthy aging and longevity.

Cederberg GmbH 

Binningen · Since 2008

Cederberg GmbH is an international healthcare company focused on developing and commercialising patent-protected medicines and medical devices. Its activities include speciality prescription pharmaceuticals and medical devices for areas such as gastroenterology, gynaecology, urology and endocrinology, and commercial products include Moventig®, Tostran®, Rectogesic® and Gynomunal®.

Celldex Therapeutics Switzerland GmbH 

Zug · Since 2018

Celldex Therapeutics Switzerland GmbH is a biopharmaceutical company developing antibody-based immunotherapies. Its pipeline includes barzolvolimab, a humanized monoclonal antibody antagonist of KIT, and CDX-622, a bispecific antibody targeting TSLP and SCF, aimed at treating allergic, inflammatory and autoimmune conditions.

Cellerys AG 

Schlieren · Since 2015

The core activity of Cellerys AG is the development of therapies for the treatment of autoimmune diseases, particularly multiple sclerosis, through the application of immunotherapies and cell therapies. The company focuses on the development of EpiTCer-based therapies, which aim to modulate the immune response to autoreactive T-cells. Cellerys conducts clinical trials and collaborates with partners such as Novartis and TETEC to develop and market its therapies.

Cellis AG 

Zug · Since 2024

The core activity of Cellis is the development of cell-based cancer treatments, in particular through the application of a platform technology that enables targeted delivery of active substances directly into cancer cells and modifies the tumor microenvironment to inhibit the growth of cancer cells.

CELLnTEC advanced cell systems AG 

Bern · Since 2002

The core activity of CELLnTEC is the development and manufacture of products and technologies for precision cell culture, particularly cell culture media designed for research and clinical applications. The company offers a range of products, including basic and specialized media, primary cells and complementary reagents required for cell culture and the development of cell therapies.

CELL RECEPTOR SA 

Geneva · Since 2015

CELL RECEPTOR SA develops a novel cell-biology-based therapy for cancer and autoimmune diseases. It researches an extracellular signalling mechanism and develops compounds that block interactions between tumour cells and platelets to reduce tumour growth, metastasis and chemoresistance.

CellShield AG 

Gersau · Since 2019

CellShield AG is an investment-focused company that manages capital allocation, supports revenue-generating projects and aims to secure returns.

cellvie AG 

Zurich · Since 2020

The core activity of cellvie is the development of cell-based medicines, in particular by exploiting the therapeutic potential of mitochondria. The company focuses on the development of Therapeutic Mitochondrial Transplantation (TMT), a novel treatment approach aimed at improving cellular energy production and thereby treating various diseases and conditions such as ischemia-reperfusion injury, aging and others.